Seminars in Oncology
Volume 36 , Pages S2-S16 , August 2009

Central Nervous System Disease in Hematologic Malignancies: Historical Perspective and Practical Applications

  • Ching-Hon Pui

      Affiliations

    • St. Jude's Children's Research Hospital, Memphis, TN
    • Corresponding Author InformationAddress correspondence to Ching-Hon Pui, MD, St. Jude's Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105
    • ,
  • Eckhard Thiel

      Affiliations

    • Charité University Medicine Berlin, Berlin, Germany

References 

  1. Simone JV. History of the treatment of childhood ALL: a paradigm for cancer cure. Best Pract Res Clin Haematol. 2006;19:353–359
  2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–178
  3. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9:257–268
  4. Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82:733–739
  5. Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Monting J, Behringer DM. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis—a single centre experience. Br J Haematol. 2004;124:762–768
  6. Phillips ME, Ryals TJ, Kambhu SA, Yuh WT. Neoplastic vs inflammatory meningeal enhancement with Gd-DTPA. J Comput Assist Tomogr. 1990;14:536–541
  7. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go?. Semin Oncol. 2000;27:540–559
  8. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105:496–502
  9. Bromberg JEC, Breems DA, Kraan J, Bikker G, van der Holt B, Smitt PS, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007;68:1674–1679
  10. Brem SS, Bierman PJ, Black P, Brem H, Chamberlain MC, Chiocca EA, et al. Central nervous system cancers. J Natl Compr Canc Netw. 2008;6:456–504
  11. Rhodes CH, Glantz MJ, Glantz L, Lekos A, Sorenson GD, Honsinger C, et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer. 1996;77:543–548
  12. Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology. 2002;58:390–396
  13. Bhojwani D, Pui CH. Intrathecal liposomal cytarabine: more friend than foe?. Leuk Lymphoma. 2008;49:1427–1430
  14. Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329:314–319
  15. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18–24
  16. Burger B, Zimmermann M, Mann G, Kühl J, Löning L, Riehm H, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21:184–188
  17. Gilchrist GS, Tubergen DG, Sather HN, et al. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group report. J Clin Oncol. 1994;12:2594–2600
  18. te Loo DM, Kamps WA, van der Does-van den Berg A, van Wering ER, de Graaf SS. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group. J Clin Oncol. 2006;24:2332–2336
  19. van den Berg H, Vet R, den Ouden E, Behrendt H. Significance of lymphoblasts in cerebrospinal fluid in newly diagnosed pediatric acute lymphoblastic malignancies with bone marrow involvement: possible benefit of dexamethasone. Med Pediatr Oncol. 1995;25:22–27
  20. Gajjar A, Harrison PL, Sandlund JT, Rivera GK, Ribeiro RC, Rubnitz JE, et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood. 2000;96:3381–3384
  21. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:(in press)
  22. Howard SC, Gajjar AJ, Cheng C, Kritchevsky SB, Somes GW, Harrison PL, et al. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA. 2002;288:2001–2007
  23. Conter V, Schrappe M, Aricü M, Reiter A, Rizzari C, Dördelmann M, et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC and good response to prednisone. J Clin Oncol. 1997;15:2786–2791
  24. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21:3616–3622
  25. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90 (German-Austrian-Swiss ALL-BFM Study Group). Blood. 2000;95:3310–3322
  26. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005;105:4752–4758
  27. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet. 2002;359:1033–1034
  28. Cario G, Izraeli S, Teichert A, Rhein P, Skokowa J, Möricke A, et al. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J Clin Oncol. 2007;25:4813–4820
  29. Wu S, Burmeister T, Baldus C, Schwartz S, Notter M, Goekbuget N, et al. Low expression of IL-15 in adult B-lineage acute lymphoblastic leukemia is associated with central nervous system involvement at initial presentation [abstract 2389]. Blood. 2007;110
  30. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86:2091–2097
  31. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006;108:465–472
  32. Fière D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy (The French Group on Therapy for Adult Acute Lymphoblastic Leukemia). J Clin Oncol. 1993;11:1990–2001
  33. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547–561
  34. Petersdorf SH, Kopecky KJ, Head DR, Boldt DH, Balcerzak SP, Wun T, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group study. Leukemia. 2001;15:208–216
  35. Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood. 1998;72:1784–1789
  36. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Löffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87:495–508
  37. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer. 2006;106:2540–2546
  38. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809–3817
  39. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129:734–745
  40. Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids (Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function). Am J Med. 1997;63:200–207
  41. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5:202–207
  42. Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol. 2005;23:6489–6498
  43. Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21:1798–1809
  44. Pui CH, Relling MV, Evans WE. Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?. Leuk Lymphoma. 2006;47:2431–2432
  45. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896–904
  46. Stork LC, Sather H, Hutchinson R. Comparison of mercaptopurine (mp) with thioguanine (tg) and it methotrexate with it “triples” (itt) in children with sr-all: results of ccg1952 [abstract 585]. Blood. 2002;100:156a
  47. Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 2006;368:1339–1348
  48. Jacobs SS, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, et al. Children's Oncology Group; National Cancer Institute Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). Pediatr Blood Cancer. 2007;49:250–255
  49. Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, et al. Children's Oncology Group Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood. 2006;108:1165–1173
  50. Rubnitz J, Razzouk B, Bowman P, Dahl G, Lacayo N, Taub J, et al. Improved remission induction rate of childhood AML: preliminary results of the AML02 trial [abstract 275]. Blood. 2005;106(part 1 of 2):84a
  51. Blaney SM, Poplack DG, Godwin K, McCully CL, Murphy R, Balis FM. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol. 1995;13:177–179
  52. Armon C, Evans RW. Addendum to assessment: prevention of post-lumbar puncture headaches: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2005;65:510–512
  53. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352:1791–1798
  54. Baxter AL, Fisher RG, Burke BL, Goldblatt SS, Isaacman DJ, Lawson ML. Local anesthetic and stylet styles: factors associated with resident lumbar puncture success. Pediatrics. 2006;117:876–881
  55. Pui CH, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640–649
  56. Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont M, Pullen J, et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study. J Clin Oncol. 2006;24:3142–3149
  57. Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002;94:773–779
  58. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–950
  59. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, et al. Société Française d'Oncologie Pédiatrique The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370–3379
  60. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, et al. BFM Group The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948–958
  61. Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004;22:3916–3921
  62. Rueda Dominguez A, Olmos Hidalgo D, Viciana Garrido R, Torres Sanchez E. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Transl Oncol. 2005;7:232–238
  63. Kim S, Khatibi S, Howell SB, McCully C, Balis FM, Poplack DG. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res. 1993;53:1596–1598
  64. Chamberlain MC, Kormanik P, Howell SB, Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol. 1995;52:912–917
  65. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, et al. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–3116
  66. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer. 2001;84:157–163
  67. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109:3214–3218
  68. Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W, et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol. 2007;29:222–226
  69. McClune B, Buadi FK, Aslam N, Przepiorka D. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma. 2007;48:1849–1851
  70. Parasole R, Menna G, Marra N, Petruzziello F, Locatelli F, Mangione A, et al. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions. Leuk Lymphoma. 2008;49:1553–1559
  71. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res. 1989;49:736–741
  72. Fisher PG, Kadan-Lottick NS, Korones DN. Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol. 2002;24:274–278
  73. Hoelzer D, Gokbuget N. Treatment of lymphoblastic lymphoma in adults. Best Pract Res Clin Haematol. 2002;15:713–728
  74. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol. 1999;17:2479–2485
  75. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13:1099–1107
  76. McMillan A. Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol. 2005;131:13–21
  77. Aviles A, Delgado S, Nambo MJ, Neri N, Murillo E, Cleto S. Primary breast lymphoma: results of a controlled clinical trial. Oncology. 2005;69:256–260
  78. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. International Extranodal Lymphoma Study Group Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21:20–27
  79. Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol. 2004;126:202–208
  80. Montserrat E, Bosch F, Lopez-Guillermo A, et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol. 1996;14:941–944
  81. Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol. 1999;78:145–149
  82. Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, et al. German Primary Central Nervous System Lymphoma Study Group Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80:159–165
  83. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15:129–133
  84. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178–1184
  85. Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature. Semin Neurol. 2004;24:395–404
  86. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, et al. Central nervous system relapse in non-Hodgkin lymphoma (A single-center study of 532 patients). Arch Neurol. 1997;54:854–859
  87. Tomita N, Kodama F, Sakai R, Koharasawa H, Hattori M, Taguchi J, et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma. 2000;38:335–343
  88. Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma—a multivariate analysis. Acta Oncol. 1996;35:703–708
  89. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients (Groupe d'Etudes des Lymphomes de l'Adulte). Ann Oncol. 2000;11:685–690
  90. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149–157
  91. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Groupe d'Etude des Lymphomes de l'Adulte Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284–4289
  92. Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma. 2002;43:587–593
  93. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev. 2006;20:319–332
  94. Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol. 2006;85:45–50
  95. Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant. 2005;11:93–100
  96. Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000;6:352–358
  97. Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome—a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol. 1994;12:2415–2422
  98. Fischer L, Korfel A, Lupp V. Kombinierte systemische und intrathekale Chemotherapie mit nachfolgender Hochdosischemotherapie und autologer Stammzelltransplantation bei ZNS-Rezidiven aggressiver Lymphome. http://www.lymphome.de/Gruppen/G-PCNSL-SG/Protokolle/NHL-ZNS-Rezidiv/index.jsp(home page of the German Competence Network Malignant Lymphomas); 2007
  99. Fischer L, Korfel A, Jahnke K, Kiewe P, Thiel E. High-dose methotrexate and ifosfamide for CNS relapse of aggressive lymphoma [abstract 12524]. J Clin Oncol. 2007;25:606s
  100. MacKintosh FR, Colby TV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FP, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer. 1982;49:586–595
  101. Bashir RM, Bierman PJ, Vose JM, Weisenburger DD, Armitage JO. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol. 1991;14:478–482
  102. Zinzani PL, Magagnoli M, Frezza G, Prologo G, Gherlinzoni F, Bendandi M, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma. 1999;32:571–576
  103. Ersboll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol. 1985;35:487–496
  104. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol. 1990;8:141–145
  105. Buckstein R, Lim W, Franssen E, Imrie KL. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma. 2003;44:955–962
  106. Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol. 2005;131:193–200
  107. Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? (Dutch HOVON Group). Ann Oncol. 1998;9:191–194

 STATEMENT OF CONFLICT OF INTEREST: The authors received honoraria for lectures from Mundipharma.

PII: S0093-7754(09)00092-X

doi: 10.1053/j.seminoncol.2009.05.002

Seminars in Oncology
Volume 36 , Pages S2-S16 , August 2009

Article Tools

* Image Usage & Resolution